New article published on 17 July 2018 in npj  Vaccines: “Down-selection of the VAR2CSA DBL1-2 expressed in E. coli as a lead antigen for placental malaria vaccine development”.

On 20/21 November, EVI will celebrate its 20th anniversary with a symposium in Heidelberg, Germany. A draft agenda is now available.

If you are interested in attending in the symposium please fill in the application form using the following LINK. We will contact you in due course.

See attached document for more information surrounding the symposium.

First call for training modules

EVI and Processing personal data on the basis of the EU/EEA General Data Protection Regulation

Phase II clinical trials in Sudan of a therapeutic vaccine to prevent post kala azar dermal leishmaniasis to be supported by European & Developing Countries Clinical Trials Partnership

EVI 20th Anniversary Symposium in Heidelberg, Germany, 20-21 November 2018

European Vaccine Initiative reports positive clinical trial results for two malaria vaccines and calls for further increase in investments into malaria research and development

TRANSVAC is an infrastructure project that aims to accelerate the development of effective vaccines urgently needed to address European and global health challenges.  This short movie explains you what the whole initiative is about.